Tatva Chintan Pharma Chem Ltd

Tatva Chintan Pharma Chem Ltd

Tatva Chintan Pharma Chem Ltd has announced a schedule of analyst/investor meeting under SEBI regulations, to be held on October 26, 2026, with Motilal Oswal Investment Advisors Limited. The meeting will be a virtual one-on-one meeting and will not involve the sharing of confidential or unpublished price-sensitive information.

Tatva Chintan Pharma Chem Ltd

Tatva Chintan Pharma Chem Ltd has scheduled an earnings call on October 19, 2026, to discuss its financial results for the quarter and half year ended September 30, 2026.

Tatva Chintan Pharma Chem Ltd

Tatva Chintan Pharma Chem Ltd has informed BSE that the meeting of the Board of Directors is scheduled on 19/10/2026 to consider and approve the Standalone and Consolidated Unaudited Financial Results for the quarter and half year ended 30 September 2026.

Tatva Chintan Pharma Chem Ltd

Tatva Chintan Pharma Chem Ltd has submitted a compliance certificate under Regulation 74(5) of SEBI (DP) Regulations, 2018, confirming the acceptance or rejection of securities received for dematerialization during the quarter ended 30 September 2026.

Tatva Chintan Pharma Chem Ltd

Tatva Chintan Pharma Chem Ltd has announced the voting results of its 30th Annual General Meeting (AGM) held on September 25, 2026. The meeting was conducted through video conferencing, and all resolutions were passed with the requisite majority. The company's audited standalone and consolidated financial statements for the financial year ended March 31, 2026, were also adopted.

Tatva Chintan Pharma Chem Ltd

Tatva Chintan Pharma Chem Ltd held its 30th Annual General Meeting on September 25, 2026, through video conferencing. The meeting was attended by 56 members, and the company's financial highlights for the year ended March 31, 2026, were presented. The meeting approved the audited standalone and consolidated financial statements, declared a dividend, and appointed a new director.

Tatva Chintan Pharma Chem Ltd

Tatva Chintan Pharma Chem Ltd has closed its trading window for all Designated Persons and their immediate relatives from 01 October 2026 till 48 hours after the declaration of the Unaudited Financial Results for the quarter and half year ending 30 September 2026.

Tatva Chintan Pharma Chem Ltd

Tatva Chintan Pharma Chem Ltd has published a newspaper advertisement for its 30th Annual General Meeting scheduled on September 25, 2026, through Video Conferencing or Other Audio Visual Means.

Tatva Chintan Pharma Chem Ltd

Tatva Chintan Pharma Chem Ltd has announced the record date, book closure, and cut-off date for its 30th Annual General Meeting (AGM). The record date is September 11, 2026, and the book closure will be from September 12 to 25, 2026. The company will pay the final dividend for the financial year 2025-26 on or after October 1, 2026.

Tatva Chintan Pharma Chem Ltd

Tatva Chintan Pharma Chem Ltd has submitted its Business Responsibility and Sustainability Report (BRSR) for FY 2025-26, as per SEBI Listing Regulations.

Tatva Chintan Pharma Chem Ltd

Tatva Chintan Pharma Chem Ltd has submitted its Annual Report for the Financial Year 2025-26, along with the Notice of the 30th Annual General Meeting, as per Regulation 34(1) of the SEBI Listing Regulations.

Tatva Chintan Pharma Chem Ltd

Tatva Chintan Pharma Chem Ltd has announced the 30th AGM to be held on 25 September 2026, where the re-appointment of Mr. Chintan Nitinkumar Shah as Managing Director for a period of three years will be considered.

Tatva Chintan Pharma Chem Ltd

Tatva Chintan Pharma Chem Ltd has announced the resignation of Mr. Ajay Rawat, Assistant Vice President – Research and Development, effective from the close of business hours on 13 November 2026.

Tatva Chintan Pharma Chem Ltd

Tatva Chintan Pharma Chem Ltd has published a newspaper advertisement announcing its 30th Annual General Meeting (AGM) to be held on September 25, 2026, through video conferencing.

Tatva Chintan Pharma Chem Ltd

Tatva Chintan Pharma Chem Ltd declares final dividend for FY 2025-26, with tax deduction at source (TDS) applicable to shareholders. Resident individuals with aggregate dividend below Rs. 10,000 are exempt from TDS. Shareholders can submit self-declaration forms for lower tax rates or exemptions.

Tatva Chintan Pharma Chem Ltd

Tatva Chintan Pharma Chem Ltd has announced a schedule of analyst/investor meetings, which will be held on August 12, 2026, with Ambit Global Private and TA Associate. The meetings will be virtual and will not include any confidential or unpublished price-sensitive information.

Tatva Chintan Pharma Chem Ltd

Tatva Chintan Pharma Chem Ltd has announced a schedule of analyst/investor meetings under SEBI regulations, with two virtual meetings on August 12, 2026, with Ambit Global Private and TA Associate.

Tatva Chintan Pharma Chem Ltd

Tatva Chintan Pharma Chem Ltd has announced an analyst/investor meeting under SEBI regulations, with a virtual meeting scheduled on August 6, 2026. The company will discuss publicly available information and not share any confidential or unpublished price-sensitive information.

Tatva Chintan Pharma Chem Ltd

Tatva Chintan Pharma Chem Ltd has announced an analyst/investor meeting under SEBI regulations, with ChrysCapital Associates participating on August 6, 2026. The meeting will be held virtually and will refer to publicly available information. No unpublished price-sensitive information will be shared.

Tatva Chintan Pharma Chem Ltd

Tatva Chintan Pharma Chem Ltd has announced a schedule of analyst/investor meeting under SEBI regulations, with a one-to-one meeting with Motilal Oswal AMC on July 31, 2026.